Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6M | -6M | -6M | -3M | -3M |
| Operating Income | -67M | -81M | -76M | -64M | -50M |
| EBITDA | -53M | -64M | -74M | -55M | -47M |
| Net Income | -59M | -71M | -64M | -58M | -50M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.27
-3.81% today
1Y Change
+192.44%
Window
Jun 26, 2025 → Jun 24, 2026
Coverage: 249 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nautilus Biotechnology, Inc. (NAUT) is a Healthcare stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $2.27 and up 192.4% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +16.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +16.1%, free cash flow +15.2% with operating margin 0.0% and ROIC -37.0%. Stock Foundry combines NAUT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NAUT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NAUT Max Drawdown
-45.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NAUT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$50.3M
+13.1% YoY
Free Cash Flow
-$41.5M
+13.8% YoY
Revenue Growth
+0.0%
EPS Growth
+16.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -6M | -6M | -6M | -3M | -3M |
| Operating Income | -67M | -81M | -76M | -64M | -50M |
| EBITDA | -53M | -64M | -74M | -55M | -47M |
| Net Income | -59M | -71M | -64M | -58M | -50M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 28M | 19M | 115M | 186M |
| Total Assets | 191M | 243M | 306M | 350M | 398M |
| Total Liabilities | 34M | 34M | 40M | 35M | 35M |
| Shareholder Equity | 157M | 209M | 265M | 315M | 364M |
| Total Debt | 30M | 30M | 35M | 30M | 30M |
| Net Debt | 18M | 3M | 15M | -84M | -156M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
39M
+14.3% YoY
Capital Expenditures
2M
+2.4% YoY
Free Cash Flow
42M
+13.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.0%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.